Účtovná hodnota akcie spoločnosti Adma Biologics Inc
Aká je hodnota metriky Účtovná hodnota akcie spoločnosti Adma Biologics Inc?
Hodnota metriky Účtovná hodnota akcie spoločnosti Adma Biologics Inc je 3.28
Aká je definícia metriky Účtovná hodnota akcie?
Účtovná hodnota akcie (Book/Share) sa rovná majetku spoločnosti mínus záväzky spoločnosti podelené počtom vydaných akcií.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Účtovná hodnota akcie spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Adma Biologics Inc
Čomu sa venuje spoločnosť Adma Biologics Inc?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Firmy s metrikou účtovná hodnota akcie podobnou spoločnosti Adma Biologics Inc
- Hodnota metriky Účtovná hodnota akcie spoločnosti ValiRx plc je 3.27
- Hodnota metriky Účtovná hodnota akcie spoločnosti Caspian Sunrise plc je 3.27
- Hodnota metriky Účtovná hodnota akcie spoločnosti ADTRAN Inc je 3.27
- Hodnota metriky Účtovná hodnota akcie spoločnosti Innergex Renewable je 3.27
- Hodnota metriky Účtovná hodnota akcie spoločnosti Express je 3.27
- Hodnota metriky Účtovná hodnota akcie spoločnosti Uni-President China Ltd je 3.28
- Hodnota metriky Účtovná hodnota akcie spoločnosti Adma Biologics Inc je 3.28
- Hodnota metriky Účtovná hodnota akcie spoločnosti AerSale je 3.28
- Hodnota metriky Účtovná hodnota akcie spoločnosti Collins Foods je 3.28
- Hodnota metriky Účtovná hodnota akcie spoločnosti Teranga Gold je 3.28
- Hodnota metriky Účtovná hodnota akcie spoločnosti Smartgroup Ltd je 3.28
- Hodnota metriky Účtovná hodnota akcie spoločnosti Eagle Nice (International) je 3.28
- Hodnota metriky Účtovná hodnota akcie spoločnosti Adtran je 3.29